Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 143

Sort by

Sort Order Select

Journal Articles

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study

Blood blood.2024027408.

https://doi.org/10.1182/blood.2024027408

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Martin Curtis, Nikki Daskalakis, Matteo Giovanni Della Porta, Hartmut Döhner, Amber D'Souza, James P. Dugan, Jordi Esteve Reyner, Matthew Exum, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Sara Garrido Paniagua, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop M. Kantarjian, Marina Konopleva, Jan Krönke, Min Chul Kwon, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Giovanni Martinelli, Daniel Morillo Giles, Joseph Murphy, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sravanti Rangaraju, Christoph Röllig, Olga Salamero, Madhu Sanga, Tim Sauer, Emma Searle, Natalia Tovar, Trevor Tucker, Nicolas Vallet, Lachlin Vaughan, Gala Vega, Paresh Vyas, Andrew Wei

Blood (2024) 144 (Supplement 1): 215.

https://doi.org/10.1182/blood-2024-207072

Published: 2024

Journal Articles

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Blood (2024) 144 (Supplement 1): 212.

https://doi.org/10.1182/blood-2024-207106

Published: 2024

Journal Articles

Mutational Landscape and Depth of Response in Patients with Acute Myeloid Leukemia (AML) Treated with Magrolimab in Combination with Venetoclax and Azacitidine Compared to Placebo

Lisa D.S. Johnson, Shan Tang, Yajia Zhang, Marlen Metzner, Lisa Aviles, Francois Kavelaars, Eyelet Morrow, Damien Vitters, Kenneth Caldwell, Peter J. M. Valk, Paresh Vyas

Blood (2024) 144 (Supplement 1): 2914.

https://doi.org/10.1182/blood-2024-203692

Published: 2024

Journal Articles

Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1 -Mutated Myeloid Malignancies

Blood (2024) 144 (Supplement 1): 642.

https://doi.org/10.1182/blood-2024-201970

Published: 2024

Journal Articles

Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial

Blood (2024) 144 (Supplement 1): 968.

https://doi.org/10.1182/blood-2024-198419

Published: 2024

Journal Articles

Results from the Great Britain AML Real World Evidence (ARC) Initiative - a Centre-Based Chart Review Study to Assess Treatment Outcomes of Venetoclax for the Treatment of Acute Myeloid Leukemia

Jenny O'Nions, Gerardo Errico, Lajos Floro, Vidhya Murthy, Connor Sweeney, Harpreet Kaur, Unmesh Mohite, Robert Ayto, Caroline Alvares, Aaron D. Goldberg, Kathryn Moulton, Hanna Kew, Ewa Kalinowska, Yanqing Xu, Paresh Vyas

Blood (2024) 144 (Supplement 1): 7932.

https://doi.org/10.1182/blood-2024-209926

Published: 2024

Journal Articles

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

Blood (2023) 142 (20): 1697–1707.

https://doi.org/10.1182/blood.2023020630

Published: 2023

Includes: Supplemental data

Journal Articles

Changing treatment changing prognosis of mutations

Paresh Vyas

Blood (2023) 142 (19): 1583–1585.

https://doi.org/10.1182/blood.2023021769

Published: 2023

Journal Articles

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

Blood (2023) 142 (Supplement 1): 57.

https://doi.org/10.1182/blood-2023-172422

Published: 2023

Journal Articles

Outcomes for Children with High Risk Acute Myeloid Leukemia on the Myechild 01 International Phase III Clinical Trial

Blood (2023) 142 (Supplement 1): 730.

https://doi.org/10.1182/blood-2023-181593

Published: 2023

Journal Articles

Sustained MYB Activity Is Necessary for Oncogenic Transcription in KMT2A -Rearranged Acute Lymphoblastic Leukemia through Enhancer-Promoter Interactions and Epigenetic Modifications at Enhancers

I-Jun Lau, Joe R Harman, Nicole E Jackson, Nicholas Denny, Alastair L Smith, Paresh Vyas, James Oliver Davies, Jim Hughes, Nicholas Crump, Thomas Arthur Milne

Blood (2023) 142 (Supplement 1): 40.

https://doi.org/10.1182/blood-2023-185172

Published: 2023

Journal Articles

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2906.

https://doi.org/10.1182/blood-2023-173413

Published: 2023

Journal Articles

GATA1 Target Gene CSF2RB Is Functionally Coupled to MPL and Marks a TPO-Dependent Preleukemic TAM Cell Population Sustained By the Fetal Liver but Not Bone Marrow

David Cruz Hernandez, Nicolas Papadopoulos, Elise Sepulchre, Marlen Metzner, Batchimeg Usukhbayar, Mirian Angulo Salazar, Leila Varghese, Gabriel Levy, Irene Roberts, Stefan N Constantinescu, Paresh Vyas

Blood (2023) 142 (Supplement 1): 404.

https://doi.org/10.1182/blood-2023-174449

Published: 2023

Journal Articles

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

Blood (2023) 141 (2): 156–167.

https://doi.org/10.1182/blood.2021014901

Published: 2023

Includes: Supplemental data

Journal Articles

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 145–149.

https://doi.org/10.1182/blood-2022-158030

Published: 2022

Journal Articles

Nature of Clinical Response and Depth of Molecular Response in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated with Magrolimab with Azacitidine

Lisa Johnson, Yajia Zhang, Biao Li, Lisa Aviles, Indu Lal, Giri Ramsingh, Naval Daver, Paresh Vyas, David A. Sallman

Blood (2022) 140 (Supplement 1): 6934–6935.

https://doi.org/10.1182/blood-2022-160337

Published: 2022

Journal Articles

Single Cell Characterisation of Transcriptional Programmes of Responsive and Resistant Leukaemic Progenitors in IDH2 -Mutant Acute Myeloid Leukaemia in the AG221-AML-005 Study

Prodromos Chatzikyriakou, Douglas RA Silveira, Maria del Pilar Casares Aláez, Batchimeg Usukhbayar, Marlen Metzner, Paresh Vyas, Anita K. Gandhi, Alberto Risueño, Maroof Hasan, Lynn Quek

Blood (2022) 140 (Supplement 1): 3414–3415.

https://doi.org/10.1182/blood-2022-163717

Published: 2022

Journal Articles

Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase 3 ( FLT3 ) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia

Cristina Papayannidis, Blanca Boluda, Jonathan Canaani, Pascal Turlure, Ann De Becker, Anand Tandra, Dina Elsouda, Arnaud Houweling, Anil Upadhyay, Isabelle Wouters, Paresh Vyas

Blood (2022) 140 (Supplement 1): 11641–11643.

https://doi.org/10.1182/blood-2022-156296

Published: 2022

Journal Articles

Dysregulation of Stem-Progenitor and Differentiation Programmes through Modulation of Bivalent Chromatin Drives Leukemogenesis in Mutant IDH2 Acute Myeloid Leukaemia

Douglas RA RA Silveira, Prodromos Chatzikyriakou, Maria del Pilar Casares Alaez, Sarah Mackie, Roan Hulks, Olena Yavorska, Paulina Siejka-Zielinska, Marlen Metzner, Alastair Smith, Batchimeg Usukhbayar, Virginie Penard-Lacronique, Chunxiao Song, Anita K. Gandhi, Maroof Hasan, Paresh Vyas, Thomas A. Milne, Skirmantas Kriaucionis, Lynn Quek

Blood (2022) 140 (Supplement 1): 8698–8699.

https://doi.org/10.1182/blood-2022-165898

Published: 2022

NARROW

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Mutational Landscape and Depth of Response in Patients with Acute Myeloid Leukemia (AML) Treated with Magrolimab in Combination with Venetoclax and Azacitidine Compared to Placebo

Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1 -Mutated Myeloid Malignancies

Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial

Results from the Great Britain AML Real World Evidence (ARC) Initiative - a Centre-Based Chart Review Study to Assess Treatment Outcomes of Venetoclax for the Treatment of Acute Myeloid Leukemia

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

Changing treatment changing prognosis of mutations

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

Outcomes for Children with High Risk Acute Myeloid Leukemia on the Myechild 01 International Phase III Clinical Trial

Sustained MYB Activity Is Necessary for Oncogenic Transcription in KMT2A -Rearranged Acute Lymphoblastic Leukemia through Enhancer-Promoter Interactions and Epigenetic Modifications at Enhancers

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

GATA1 Target Gene CSF2RB Is Functionally Coupled to MPL and Marks a TPO-Dependent Preleukemic TAM Cell Population Sustained By the Fetal Liver but Not Bone Marrow

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Nature of Clinical Response and Depth of Molecular Response in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated with Magrolimab with Azacitidine

Single Cell Characterisation of Transcriptional Programmes of Responsive and Resistant Leukaemic Progenitors in IDH2 -Mutant Acute Myeloid Leukaemia in the AG221-AML-005 Study

Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase 3 ( FLT3 ) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia

Dysregulation of Stem-Progenitor and Differentiation Programmes through Modulation of Bivalent Chromatin Drives Leukemogenesis in Mutant IDH2 Acute Myeloid Leukaemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only